These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 35746482)
21. Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose. Vicenti I; Basso M; Gatti F; Scaggiante R; Boccuto A; Zago D; Modolo E; Dragoni F; Parisi SG; Zazzi M Int J Infect Dis; 2021 Nov; 112():40-44. PubMed ID: 34481967 [TBL] [Abstract][Full Text] [Related]
22. A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants. Lee IJ; Sun CP; Wu PY; Lan YH; Wang IH; Liu WC; Yuan JP; Chang YW; Tseng SC; Tsung SI; Chou YC; Kumari M; Lin YS; Chen HF; Chen TY; Lin CC; Chiu CW; Hsieh CH; Chuang CY; Cheng CM; Lin HT; Chen WY; Hsu FF; Hong MH; Liao CC; Chang CS; Liang JJ; Ma HH; Chiang MT; Liao HN; Ko HY; Chen LY; Ko YA; Yu PY; Yang TJ; Chiang PC; Hsu ST; Lin YL; Lee CC; Wu HC; Tao MH J Biomed Sci; 2022 Jul; 29(1):49. PubMed ID: 35799178 [TBL] [Abstract][Full Text] [Related]
23. Comparison of total and neutralizing SARS-CoV-2 spike antibodies against omicron and other variants in paired samples after two or three doses of mRNA vaccine. Debes AK; Xiao S; Egbert ER; Caturegli P; Sitaras I; Pekosz A; Milstone AM medRxiv; 2022 Jan; ():. PubMed ID: 35132427 [TBL] [Abstract][Full Text] [Related]
24. Single-dose BNT162b2 mRNA COVID-19 vaccine significantly boosts neutralizing antibody response in health care workers recovering from asymptomatic or mild natural SARS-CoV-2 infection. Vicenti I; Gatti F; Scaggiante R; Boccuto A; Zago D; Basso M; Dragoni F; Zazzi M; Parisi SG Int J Infect Dis; 2021 Jul; 108():176-178. PubMed ID: 34022329 [TBL] [Abstract][Full Text] [Related]
25. Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2. Siracusano G; Ruggiero A; Bisoffi Z; Piubelli C; Carbonare LD; Valenti MT; Mayora-Neto M; Temperton N; Lopalco L; Zipeto D J Transl Med; 2022 Jan; 20(1):22. PubMed ID: 34998405 [TBL] [Abstract][Full Text] [Related]
26. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. Edara VV; Manning KE; Ellis M; Lai L; Moore KM; Foster SL; Floyd K; Davis-Gardner ME; Mantus G; Nyhoff LE; Bechnak S; Alaaeddine G; Naji A; Samaha H; Lee M; Bristow L; Hussaini L; Ciric CR; Nguyen PV; Gagne M; Roberts-Torres J; Henry AR; Godbole S; Grakoui A; Sexton M; Piantadosi A; Waggoner JJ; Douek DC; Anderson EJ; Rouphael N; Wrammert J; Suthar MS bioRxiv; 2021 Dec; ():. PubMed ID: 34981056 [TBL] [Abstract][Full Text] [Related]
27. SARS-CoV-2 Neutralizing Antibodies to B.1 and to BA.5 Variant after Booster Dose of BNT162b2 Vaccine in HIV Patients COVID-Naïve and on Successful Antiretroviral Therapy. Vicenti I; Basso M; Pirola N; Bragato B; Rossi MC; Giobbia M; Pascoli S; Vinci A; Caputo S; Varasi I; Biba C; Fiaschi L; Zazzi M; Parisi SG Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112782 [TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination. Trabace L; Pace L; Morgese MG; Santo IB; Galante D; Schiavone S; Cipolletta D; Rosa AM; Reveglia P; Parisi A; Tucci P; Pepe G; Sacco R; Foschino Barbaro MP; Corso G; Fasanella A Viruses; 2022 Apr; 14(4):. PubMed ID: 35458544 [TBL] [Abstract][Full Text] [Related]
29. The relationship between the number of COVID-19 vaccines and infection with Omicron ACE2 inhibition at 18-months post initial vaccination in an adult cohort of Canadian paramedics. Yap J; Kayda I; Asamoah-Boaheng M; Haig S; Kirkham T; Cheskes S; Demers P; Goldfarb D; Grunau BE Access Microbiol; 2023; 5(11):. PubMed ID: 38074102 [TBL] [Abstract][Full Text] [Related]
30. Neutralizing Antibody Responses Elicited by Inactivated Whole Virus and Genetic Vaccines against Dominant SARS-CoV-2 Variants during the Four Epidemic Peaks of COVID-19 in Colombia. Álvarez-Díaz DA; Muñoz AL; Herrera-Sepúlveda MT; Tavera-Rodríguez P; Laiton-Donato K; Franco-Muñoz C; Ruiz-Moreno HA; Galindo M; Catama JD; Bermudez-Forero A; Mercado-Reyes M Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560554 [TBL] [Abstract][Full Text] [Related]
31. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053 [TBL] [Abstract][Full Text] [Related]
32. Antibody Response against Circulating Omicron Variants 8 Months after the Third Dose of mRNA Vaccine. Anichini G; Terrosi C; Gori Savellini G; Gandolfo C; Barbagli F; Carta GA; Fabrizi S; Miceli GB; Cusi MG Vaccines (Basel); 2022 Sep; 10(9):. PubMed ID: 36146590 [TBL] [Abstract][Full Text] [Related]
33. Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern. Mohandas S; Yadav PD; Sapkal G; Shete AM; Deshpande G; Nyayanit DA; Patil D; Kadam M; Kumar A; Mote C; Jain R EBioMedicine; 2022 May; 79():103997. PubMed ID: 35405385 [TBL] [Abstract][Full Text] [Related]
34. Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants. Belik M; Jalkanen P; Lundberg R; Reinholm A; Laine L; Väisänen E; Skön M; Tähtinen PA; Ivaska L; Pakkanen SH; Häkkinen HK; Ortamo E; Pasternack A; Ritvos MA; Naves RA; Miettinen S; Sironen T; Vapalahti O; Ritvos O; Österlund P; Kantele A; Lempainen J; Kakkola L; Kolehmainen P; Julkunen I Nat Commun; 2022 May; 13(1):2476. PubMed ID: 35513437 [TBL] [Abstract][Full Text] [Related]
35. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants. Chiuppesi F; Zaia JA; Faircloth K; Johnson D; Ly M; Karpinski V; La Rosa C; Drake J; Marcia J; Acosta AM; Dempsey S; Taplitz RA; Zhou Q; Park Y; Ortega Francisco S; Kaltcheva T; Frankel PH; Rosen S; Wussow F; Dadwal S; Diamond DJ iScience; 2022 Aug; 25(8):104745. PubMed ID: 35846380 [TBL] [Abstract][Full Text] [Related]
36. BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. Vicenti I; Gatti F; Scaggiante R; Boccuto A; Zago D; Basso M; Dragoni F; Parisi SG; Zazzi M Life (Basel); 2021 Aug; 11(9):. PubMed ID: 34575045 [TBL] [Abstract][Full Text] [Related]
37. Neutralization against SARS-CoV-2 Delta/Omicron variants and B cell response after inactivated vaccination among COVID-19 convalescents. Wang H; Yuan Y; Wu B; Xiao M; Wang Z; Diao T; Zeng R; Chen L; Lei Y; Long P; Guo Y; Lai X; Wen Y; Li W; Cai H; Song L; Ni W; Zhao Y; Ouyang K; Wang J; Wang Q; Liu L; Wang C; Pan A; Li X; Gong R; Wu T Front Med; 2023 Aug; 17(4):747-757. PubMed ID: 36738428 [TBL] [Abstract][Full Text] [Related]
38. An Analysis of the Neutralizing Antibodies against the Main SARS-CoV-2 Variants in Healthcare Workers (HCWs) Vaccinated against or Infected by SARS-CoV-2. Immordino P; Pisciotta V; Amodio E; Bonura C; Bonura F; Cacioppo F; Calamusa G; Capra G; Casuccio A; De Grazia S; Genovese D; Graci D; Lacca G; Sanfilippo GL; Verso MG; Giammanco GM; Ferraro D Vaccines (Basel); 2023 Nov; 11(11):. PubMed ID: 38006034 [TBL] [Abstract][Full Text] [Related]
39. Comprehensive Humoral and Cellular Immune Responses to SARS-CoV-2 Variants in Diverse Chinese Population. Li J; Wu J; Long Q; Wu Y; Hu X; He Y; Jiang M; Li J; Zhao L; Yang S; Chen X; Wang M; Zheng J; Wu F; Wu R; Ren L; Bu L; Wang H; Li K; Fu L; Zhang G; Zheng Y; Gao Z Research (Wash D C); 2022; 2022():9873831. PubMed ID: 35935138 [TBL] [Abstract][Full Text] [Related]
40. Alum/CpG Adjuvanted Inactivated COVID-19 Vaccine with Protective Efficacy against SARS-CoV-2 and Variants. Zhang Y; Zheng X; Sheng W; Liang H; Zhao Y; Zhu X; Yang R; Zhang Y; Dong X; Li W; Pei F; Ding L; Chang Z; Deng L; Yuan G; Yang Z; Zhu D; Yang X; Wang H Vaccines (Basel); 2022 Jul; 10(8):. PubMed ID: 36016098 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]